TGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now for a tactical rebound/swing setup. TGTX is trading near short-term support after a -1.90% regular-session drop, with RSI_6 31.5 (near-oversold) and options positioning skewed bullish (puts < calls). While there’s no Intellectia signal today and no near-term news catalyst, the latest reported quarter shows very strong growth/profitability momentum, which supports dip-buying. Near-term upside targets are the pivot (30.84) and R1 (32.10); the key level to watch is the next support zone near S2 (28.80) if selling persists.
Intellectia Proprietary Trading Signals
Trend/price context: Post-market ~29.47 after a -1.90% regular-session decline (weak short-term tape). Momentum: MACD histogram is slightly positive (0.00552) but contracting, implying upside momentum is fading rather than accelerating. RSI_6 at 31.5 is near-oversold, which often favors a bounce attempt rather than fresh aggressive selling. Moving averages are converging, consistent with consolidation/transition rather than a clean trend.
Levels: Current price is just below S1 (29.577), suggesting S1 is immediate overhead resistance now; the next downside support is S2 (28.798). Upside reclaim levels are Pivot (30.838) then R1 (32.098). Base case: choppy-to-slightly weak next day/week, but improving odds over a 1-month window (pattern-based signal shows higher probability of being up over the next month).
Financial momentum: 2025/Q3 showed very strong YoY revenue growth (+92.79%) and a sharp swing in profitability (net income +9974.61% YoY; EPS 2.43, +12050% YoY), which can attract incremental buyers on dips.
Sector backdrop (from analyst commentary): improving biotech sentiment and a better M&A/in-licensing environment can lift quality single-name biopharma.
Options positioning skew (puts < calls) supports a market leaning bullish rather than defensive.
No fresh news in the past week: lacking an immediate event-driven catalyst, price may continue to trade technically (range/chop) rather than trend strongly.
Profitability quality/margins: gross margin fell to 82.63% (down ~7.01% YoY), which can temper enthusiasm if margin compression persists.
Conflicting Wall Street views: BofA maintains an Underperform rating (despite a PT raise), creating an overhang versus more bullish coverage.
Latest quarter: 2025/Q3. Revenue rose to $161.709M (+92.79% YoY), indicating strong top-line acceleration. Profitability surged: net income was $390.895M (+9974.61% YoY) and EPS was 2.43 (+12050% YoY), signaling a major step-up in earnings power versus the prior year period. The main soft spot was gross margin, which decreased to 82.63% (-7.01% YoY), suggesting some mix/expense pressure even as overall earnings expanded sharply.
Recent trend: price targets were raised by both firms mentioned, but ratings diverge.
Wall Street pros vs cons: The bullish case (JPM) supports meaningful upside and reflects confidence post-earnings/model update; the bearish case (BofA) argues the risk/reward is unattractive at current levels despite a better biotech tape. Net: mixed-to-polarized Street view, with one strongly bullish target and one clearly bearish stance.
